Tendinopathy

TendoNova wins FDA Clearance for Its New Microinvasive Ocelot Surgical Tool

Retrieved on: 
Wednesday, March 23, 2022
NFL, Tendinopathy, Podiatry, Korea Disease Control and Prevention Agency, Growth, Patient, Georgia Research Alliance, Ocelot, Sports medicine, Pain management, Pain, National Football League, Injury, Association, Technology, TENEX, Physician, Center, Athlete, NFL Player's Association Financial Registration Program, Emory University School of Medicine, Georgia Tech, Debridement, Tennis elbow, FDA, Atlanta Hawks, Elective surgery, Medical imaging

ATLANTA, March 23, 2022 /PRNewswire/ -- TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510(k) clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue.

Key Points: 
  • ATLANTA, March 23, 2022 /PRNewswire/ -- TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510(k) clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue.
  • TendoNova plans to manufacture the Ocelot in Georgia and is presently working to validate the Ocelot disposable component production.
  • Founded in 2017, TendoNova is a medical device company that is an emerging leader in microinvasive sports medicine procedures.
  • The company's initial product is the Ocelot TSD 1000, a patented, FDA cleared medical device for fragmentation or debridement of soft tissue.

ZetrOZ Signs 5-Year Agreement With US Government to Supply Employees and Military With SAM Technology

Retrieved on: 
Thursday, January 13, 2022
Telephone, Research, CIA, Arthritis, Interest, ISO, Mail, Back pain, Journal of Pain Research, GLOBE, Government, Chronic pain, Major, Knee pain, Veteran, Pain, Tendinopathy, OA, Knee, MRI, CGMP, Doc Comparato, FBI, FDA, Orthopedic surgery, Osteoarthritis, DOL, Hospital, NP-hardness, Health insurance

So much credit goes to the U.S. government for bringing this effective and practical treatment option to its hardworking employees."

Key Points: 
  • So much credit goes to the U.S. government for bringing this effective and practical treatment option to its hardworking employees."
  • Providers and hospital centers can order sam directly through the new contract and through the ZetrOZ Systems Durable Medical Equipment healthcare network directly.
  • ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut.
  • ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis.

Steven B. Orr, MD, is recognized by Continental Who's Who

Retrieved on: 
Tuesday, January 4, 2022
Family, Hospital for Special Surgery, Clinical, GLMA, ENT, Assistant professor, National Merit Scholarship Program, Research, Patient, Hospital, Guillaume Dupuytren, Duke University School of Medicine, Partner, Orthopedic surgery, Ascending limb of loop of Henle, Elbow, Dupuytren's contracture, Fellow, NYU Langone Health, MD, Awareness, Department, Forearm, Continental, Contracture, Health equity, Fifth Avenue, Technology, NYU, Tennis elbow, Wrist, Multimedia, RYC, Friends, Tendinopathy, Collection, Dentistry, Science, Hand, Medicine

NEW YORK, Jan. 4, 2022 /PRNewswire/ --Steven B. Orr, MD, is being recognized by Continental Who's Who as a Trusted Orthopedist for his superb work at RYC Orthopedics.

Key Points: 
  • NEW YORK, Jan. 4, 2022 /PRNewswire/ --Steven B. Orr, MD, is being recognized by Continental Who's Who as a Trusted Orthopedist for his superb work at RYC Orthopedics.
  • He specialized in hand and upper extremity surgeries, including conditions of the hand, wrist, forearm, and elbow.
  • From a formative age, Dr. Orr grew interested in hand surgery due to his love of playing the piano.
  • He also garnered inspiration from his father, an accomplished ENT, who gave his son a collection of scrub caps to use for surgery.

Global Orthopedic Soft Tissue Repair (Epicondylitis, Pelvic Organ Prolapse) Market Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 9, 2021
Health, Other Health, Injury, ACL, Ligament, Athlete, Patient, Industry, USD, Accident, Platelet-rich plasma, CAGR, NP-hardness, Incidence, Adoption, Bursitis, Tendon, Knee, Hospital, Application, Tendinopathy, Muscle, Bruise, Tissue paper, Medical imaging

The "Global Orthopedic Soft Tissue Repair Market, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Orthopedic Soft Tissue Repair Market, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global orthopedic soft tissue repair market size is expected to reach USD 9.6 billion by 2028 and is expected to expand at a CAGR of 6.3% from 2021 to 2028.
  • In addition, the increasing adoption of minimally invasive procedures due to growing concern over surgical scars further drives the demand for orthopedic soft tissue repair products.
  • The knee injury segment dominated the market in 2020 due to the high incidence of meniscus tear, which is a frequently occurring soft tissue knee injury among athletes
    North America dominated the market in 2020 due to an increase in healthcare spending, which makes expensive soft tissue repair surgeries more affordable
    Chapter 3 Orthopedic Soft Tissue Repair Market Variables, Trends & Scope
    Chapter 4 Orthopedic Soft Tissue Repair Market: Application Estimates & Trend Analysis
    Chapter 5 Orthopedic Soft Tissue Repair Market: Injury Location Estimates & Trend Analysis
    Chapter 6 Orthopedic Soft Tissue Repair Market: Regional Estimates & Trend Analysis: By Application and Injury Location
    Chapter 7 Orthopedic Soft Tissue Repair Market: Competitive Analysis

ZetrOZ Systems Expands Patient Access for Sustained Acoustic Medicine Treatment

Retrieved on: 
Thursday, December 2, 2021
Patient, Soft tissue injury, Sport, CEO, History of Sufism, Inflammation, Tendinopathy, Physician, Pain scale, GLOBE, Arthritis, ISO, FDA, Therapy, CGMP, Medical imaging, Pharmaceutical industry

The patient and health provider portal at samrecover.comdetails information for patients and physicians, physical therapists, chiropractors and other healthcare providers.

Key Points: 
  • The patient and health provider portal at samrecover.comdetails information for patients and physicians, physical therapists, chiropractors and other healthcare providers.
  • "Our sam technology accelerates the healing process, reducing the need for potentially addictive opioids or invasive surgery," said Dr. George Lewis, founder and CEO of ZetrOZ Systems.
  • ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut.
  • ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis.

Flora Growth Forms JV With Avaria Health and Beauty to Distribute Award-Winning Pain Products Across LATAM

Retrieved on: 
Friday, November 26, 2021
Other Health, Men, General Health, Discount, Variety, Specialty, Consumer, Convenience Store, Retail, Other Consumer, Women, Alternative Medicine, Health, Volunteering, Patient, Research, Sale, CEO, Environment, Technology, Industry, Forward-looking statement, Cannabis, Company, Arthralgia, IPO, FLGC, Tendinopathy, Nature, Pain, Kalaya, Emulsion, Flora, Oil, NASDAQ, Cannabidiol, Arthritis, Terminology, LATAM, Gel, Food, Growth, Cosmetics, Drug, Pharmaceutical industry, Risk management, Flora Growth’s Recent Financing, Avaria Health & Beauty Corp., Flora Growth Corp., FLORA GROWTH’S RECENT FINANCING, AVARIA HEALTH & BEAUTY CORP., FLORA GROWTH CORP.

Any profits from the sale of KaLaya products via FloVaria will be divided equally between Flora and Avaria, increasing the value of Floras existing distribution channels.

Key Points: 
  • Any profits from the sale of KaLaya products via FloVaria will be divided equally between Flora and Avaria, increasing the value of Floras existing distribution channels.
  • Further, Flora Lab will work to produce FloVarias cannabinoid-infused products, with an emphasis on incorporating cannabidiol (CBD), using cannabis from Floras cultivation facility.
  • Avaria has achieved impressive and continued growth of its KaLaya brand based on the quality and efficacy of the product.
  • Our team is very excited to bring their award-winning topical pain products to our LATAM distribution network, and to produce cannabinoid-infused KaLaya products at Flora Lab.

Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy

Retrieved on: 
Monday, November 1, 2021
Science, Research, Good tissue practice, Architecture, Structural Damage, Tendinopathy, Industry, Disease, Connective tissue, III, Endothelium, B cell, Patient, OA, Chronic condition, Interleukin, Journal of Biomedical Materials Research, Homeostasis, Allotransplantation, ECM, Human, Nuclear, Environment, Inflammation, Documentation, IL-6, Tissue, Sterilization, IND, Regenerative medicine, Hip, Matrix, Conditional sentence, Nonsteroidal anti-inflammatory drug, GLOBE, Culture, Show, HIV disease progression rates, Extracellular matrix, Journal, Enzyme, NF, Logging, Pharmaceutical industry, Medical device, Silk, Medical imaging

MARIETTA, Ga., Nov. 01, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion chorion membrane (mdHACM) for the treatment of debilitating conditions involving degeneration of connective tissue: osteoarthritis (OA) and tendinopathy.

Key Points: 
  • These studies reaffirm our commitment to advancing the science of amniotic tissue, said Timothy R. Wright, MIMEDX Chief Executive Officer.
  • Through our continued investment in research and clinical development, we aim to demonstrate the utility of PURION Processed mdHACM as a platform for regenerative medicine.
  • Micronized dHACM is hypothesized to target specific OA-related pathways to re-establish homeostasis, and thereby mitigate the physical effects of OA.
  • This study evaluated the effects of micronized dehydrated human amnion chorion membrane (mdHACM) on the inflammatory environment and hypervascularity associated with chronic tendon injury.

Global Patient Lateral Transfer Devices Market to 2027 - Featuring Blue Chip Medical Products, Scan Medical and Air-Matt Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 23, 2021
Medical Devices, Health, Transfer, Friction, Hospital, Injury, Tendinopathy, Patient, Lists of diseases, Caregiver, Nursing, COVID, Pallavi Patel College of Health Care Sciences, Risk, Center, Incidence, COVID 19, Low back pain

The "Global Patient Lateral Transfer Devices Market to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Patient Lateral Transfer Devices Market to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Rise in incidence of musculoskeletal disorders like tendonitis, low back pain, and others which is expected to boost the global patient lateral transfer devices market growth.
  • Also, high risk of injuries to caregivers during manual handling of patients will have the positive impact on global patient lateral transfer devices market.
  • However, lack of knowledge of using advanced devices and unavailability of qualified professionals are the restraining factors which are expected to hamper the global patient lateral transfer devices market growth.

Steven B. Orr, MD is recognized by Continental Who's Who

Retrieved on: 
Friday, September 3, 2021
Patient, National Merit Scholarship Program, Awareness, Orthopedic surgery, Clinical, MD, Assistant professor, Collection, Dupuytren's contracture, Hospital for Special Surgery, Ascending limb of loop of Henle, Contracture, Fellow, Duke University School of Medicine, Health equity, Hospital, Fifth Avenue, Guillaume Dupuytren, GLMA, Forearm, Multimedia, Tendinopathy, Department, Research, Technology, Partner, NYU Langone Health, Wrist, ENT, NYU, RYC, Continental, Friends, Family, Tennis elbow, Elbow, Dentistry

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Steven B. Orr, MD, is being recognized by Continental Who's Who as a Trusted Orthopedist for his superb work at RYC Orthopedics.

Key Points: 
  • NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Steven B. Orr, MD, is being recognized by Continental Who's Who as a Trusted Orthopedist for his superb work at RYC Orthopedics.
  • He specialized in hand and upper extremity surgeries, including conditions of the hand, wrist, forearm, and elbow.
  • From a formative age, Dr. Orr grew interested in hand surgery due to his love of playing the piano.
  • He also garnered inspiration from his father, an accomplished ENT, who gave his son a collection of scrub caps to use for surgery.

Bioventus Invests in Trice Medical Minimally Invasive Technologies

Retrieved on: 
Wednesday, August 25, 2021
SEC, Research, Organic acid, Food, Senior, Review, Securities Act of 1933, Board, Scar, Exogen, Securities Exchange Act of 1934, Pain, U.S. Securities and Exchange Commission, Evidence-based medicine, Hyaluronic acid, Forward-looking statement, Projection, Tendinopathy, Regulation of tobacco by the U.S. Food and Drug Administration, Twitter, Drug Quality and Security Act, Series, Government, Tissue, Nasdaq, Business development, Elective surgery, HA, Failure, Sports medicine, LinkedIn, Innovation, FDA, Security (finance), Company, Terminology, Growth, Acquisition, GLOBE, Physician, Risk, Patient, Annual report, COVID-19

DURHAM, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has completed a strategic investment in Trice Medical , Inc., a company focused on developing and commercializing minimally invasive technologiesfor sports medicine and orthopedic surgical procedures.

Key Points: 
  • DURHAM, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has completed a strategic investment in Trice Medical , Inc., a company focused on developing and commercializing minimally invasive technologiesfor sports medicine and orthopedic surgical procedures.
  • Bioventus and Trice have also agreed to enter into a co-development arrangement to explorethe integration of Trice technologieswith Bioventus current and future peripheral nerve stimulation (PNS) offerings of StimRouter and TalisMann in order toaccelerate adoptionof both companies products.
  • In connection with the investment, Yamamoto has been elected to serve on the Board of Trice.
  • Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.